Beckman Coulter/Princeton BioMeditech agreement

Sunday, 16 October, 2005


In a move that underscores its growing commitment to the market for rapid diagnostic medical test products, Beckman Coulter has entered into a supply relationship with Princeton BioMeditech (PBM). Under the agreement, PBM will supply a wide range of rapid diagnostic tools used at the point of medical care to Beckman Coulter's Primary Care Diagnostics business unit (PCD).

Princeton BioMeditech is a leading innovator and manufacturer of simple and rapid diagnostic products used at the point of care. The company offers more than 70 tests covering fertility management, infectious diseases, cardiac markers, drugs of abuse, cancer markers, environmental and veterinary diagnostics that enable consumers and professionals to improve speed and quality of diagnosis for better patient care.

Related News

Agilent expands cell analysis portfolio with BioTek acquisition

Agilent Technologies has signed a definitive agreement to acquire the privately owned BioTek...

IDT and 3CR collaborate on custom genotyping service

The partnership fuses IDT's oligo synthesis with 3CR's PACE Genotyping Master Mix and...

$6m investment in WA space sector

Western Australia will play a key role in the Australian Space Agency's efforts to triple the...


  • All content Copyright © 2019 Westwick-Farrow Pty Ltd